Fifty-one patients with mild hypertension were evaluated in relation to the plasma concentrations of coagulation and fibrinolysis factors äs well äs for the aggregability of their platelets.
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Materials and Methods

Patients
As criteria of hypertension, we used the repeated raeasurement of a diastolic pressure of ^ 130 mmHg both on the left and righl hand side. Fifty-one patients meeting these criteria were evaluated in this study. The group consisted of 29 males and 22 females, aged between 24 and 80 years (mean age 47 years). The systolic pressure ranged from 130 -200 mmHg (mean 164 mmHg), the diastolic pressure between 90 and 144 mmHg (mean 104 mmHg). For the classification of the hypertension we considered three subgroups: essential hypertension, renal hypertension and hormonal hypertension. In this study, all patients were classified äs belonging to the essential hypertension group. We excluded the presence of malignant hypertension by fundoscopy, ECG and X-ray of the thorax. The reference values were obtained from 50 subjectiveiy healthy individuals aged 24-50 years (mean 40 years) and known to be without hypenension.
Blood samples
Blood samples were drawn after fasting overnight, after a resting period of 20 min. Except for tissue plasminogen activator activity, all coagulation and fibrinolysis parameters were determined in citrated plasma. This was prepared by centrifugation of a mixture of nine volumes freshly drawn blood with one volume trisodium citrale (0.11 mol/1) for 30 min (1600g) at 25 °C. The plasma was stored at -70 °C in plastic tubes and thawed with tap water for 5 min before serial analysis. For the measurement of tissue plasminogen activator activity a separate tube was prepared with 0.5 ml acetate buffer (pH = 3.9) and filled with l ml citrated blood. The tube was centrifuged immediately (30 min, 1800#) and the plasma separated. The collected plasma was acidified with 20% acetic acid (final pH of the plasma sample 4.0-4.1), then stored at -70 °C in plastic tubes; it was thawed with tap water for 5 min before analysis. For the factor VIII:c determination an activated partial thrombin time (aPTT) on stage clotting assay was performed, using a deficient plasma from Behring (Marburg, FRG). Fibrin monomer concentrations were assessed with the chromogenic COA-Set FM-test of Kabi Vitrum Diagnostica. Thrombinantithrombin III was determined wilh an ELISA kit of the Behring Corporation (Marburg, FRG). D-Dimer was assayed in plasma with an ELISA method of Boehringer Mannheim Corp. (Mannheim, FRG). For plasminogen activator inhibitor the lest kit of Kabi Vitrum Diagnostiea COA-Set PAI was used. The tissue-plasminogen activator activity test was also from Kabi Vitrum Diagnostica äs well äs the antigenic tissue plasminogen activator test (Kabi Vitrum ttiagnostica, Coaliza t-PA test). The piatelet aggregation tests were performed on platelet-rich plasma which was prepared by immediate centrifugation of citrated blood (prepared äs described above) at 200 g for 10 minutes at room temperature. After gentle aspiration of the platelet-rich-plasma, using a plastic pipette, the feriiaining blood was centrifuged at 2000 £ for 10 min at room temperature, the resulting platelet-poor plasma was aspirated and subsequently centrifuged at 10000g at 4°C for 10 min to obtain platelet-free plasma. Platelet-rich plasma and platelet-free plasma were used for standardization of the end concentration of the piatelet count in the test. The ADP aggregation was performed at a thrornbocyte concentration of 200 10 9 /1·
Results
The summary statistics of the parameters are given in ') The difference between the A«« of the reversible and the non-reversible group within the hypertensives was highly significant (p < 0.0001). n. f. = not found. A max = maximal amplitude of the aggregation pattern. a reversible (normal) aggregation pattern and aggregation intensity, whereas 18/51 (35.3%) of the patients demonstrated a strengenthed (non-reversible) aggregation pattern and significantly enhanced aggregation maximum-values.
Discussion
Recently Panza et al. (20) concluded in their study on abnormal endothelium-dependent vascular relaxation in patients with essential hypertension, that endothelium mediated vasodilation is impaired in patients with essential hypertension. This defect might play an important role in the functional abnormality of elevated vascular resistance, which is observed in hypertensive patients. Under regul r circumstances the patency of the blood vessels and the fluidity of the blood is maintained by the endothelial cells. For this purpose the endothelial cells synthesize a number of active substances like fibronectin, heparan sulphate, interleukin-1, tissue plasminogen activator, plasminogen activator inhibitor, prostacyclin, nitric oxide, plateletactivating factor and endothelin-1 (21, 22) . van 
Moreover the von Wittebrand factor is known to be synthesized by endothelial cells, which is important for the platelet-vessel wall interaction (18) . Recently Struyker Boudier et aL (23) summarized the three mechanisms thought to be responsible for the overall vascular resistance increase in hypertension: the rarefaction of arterioles and capillaries, the decreased internal diameter of the arterioles and the increase of the arterial and arteriolar wall mass. We were therefore interested in possible interactions between the more resistant vessel wall and platelets and coagulation/fibrinolysis factors circulating in the blood.
In a considerable number of the patients (35.7%) we found an enhanced in vitro reactivity towards ADP (2 μιηοΙ/Ο-ίικΚκκα aggregation, which is in agreement with earlier fmdings of Yamanishi et al. (24) in patients with different stages of essential hypertension. One could speculate that this phenomenon is a sequal of the diminished prostacyclin synthesis and/or release by the endothelial cells. Isles et al. (25) and Gavras et al. (26) showed that malignant hypertension was associated with increased mean levels of fibrinogen, factor VIII:c, decreased urokinase, increased fibrin(ogen) degradation products and decreased platelet count. In our patients with relatively mild hypertension we can confirm the significant elevation of the fibrinogen level, but not that of factor VIILc. We demonstrated a significant decrease of tissue plasminogen activator activity, but a significant increase of tissue plasminogen activator antigen and the level of plasminogen activator inhibitor level.
The seeming discrepancy between activity and antigenic concentration has been described earlier by Nilsson et al. (27) in patients with venous thrombosis and defective fibrinolysis. The explanation therefore might be the complex formation between plasminogen activator and plasminogen activator inhibitor, which can only be detected in the antigenic determination. With regard to the significant enhancement of the mean plasminogen activator inhibitor concentrations, it should be mentioned that it has recently been reported that two pools of plasminogen activator inhibitor-1 exist in blood, which may originate from different cell types. The first one is the free plasma pool, which might be synthesized and secreted by endothelial cells and/or hepatocytes s reported by Loskutoff (28) and Sprengers (39), but this is not unambiguously established. The second pool of plasminogen activator inhibitor has been detennined in the α-granules of the platelets (30) and thus in megakaryocytes. The last pool might be the origin of the increased plasminogen activtor inhibitor concentrat ions in this patient group. As we could demonstrate elevated platelet reactivity, which is indicative for platelet activation, one might conclude that there will be some platelet plasminogen activator inhibitor release, especially in the presence of a specific Stimulus like thrombin.
That thrombin is present can be concluded from the significantly enhanced mean values for thr mbin^an-tithrombin III and fibrin monomers, whereas the mean D-dimer levels are significantly enhanced too, the mean value, however, being still within the reference r nge. n the basis of the percentages of values above the upper reference r nge limit (for fibrin monomers 60.8%, for D-dimer 29.4%) there seems to be a discrepancy between coagulation activation and reactive fibrinolysis, which is concordant however with the behavio r of tissue plasminogen activator activity and plasminogen activator inhibitor.
Besides platelet aggregability, tissue plasminogen activator and plasminogen activator inhibitor have been reported to be major risk factors for the development of cardiovascular disease (10 -15) , whereas enhanced fibrinogen levels have been reported to be related to the additional enhanced risk for c rdiovascular dis? ease (16, 17) . In summary we therefore conclude that both coagulation and fibrinolysis s well s the platelets are impaired in hypertension and that a number of risk factors for thrombophilia is present in this group of hypertensive patients.
